AmperSand has successfully raised $65 million in a Series B funding round, with support from Eli Lilly. The funding will be used to further enhance their innovative capabilities.
Amount Raised
$65 Million
Round Type
Series B
BostonBiotechnologyInvestors
Description
AmperSand has secured $65 million in a Series B funding round. Eli Lilly has joined as a lead investor, highlighting confidence in AmperSand's potential. The funds will be utilized to drive advancements in their offerings. This investment marks a significant step in AmperSand's growth journey.
Quick answer
Ampersand Biomedicines raised $65 Million in a Series B round, dated March 19, 2025. Investors: Eli Lilly & Company, Flagship Pioneering and Eli Lilly. Ampersand Biomedicines is based in Boston, Massachusetts, United States.
- How much did Ampersand Biomedicines raise?
- Ampersand Biomedicines raised $65 Million in a Series B round on March 19, 2025.
- Who invested in Ampersand Biomedicines?
- Eli Lilly & Company, Flagship Pioneering and Eli Lilly are named as investors in this round.
- What does Ampersand Biomedicines do?
- Ampersand Biomedicines enables a new way of designing programmable medicines that work precisely where needed in the body and nowhere else.
- Where is Ampersand Biomedicines based and how big is it?
- Ampersand Biomedicines is based in Boston, Massachusetts, United States. Fundz records about 45 employees.
- Who are the decision-makers at Ampersand Biomedicines?
- Fundz holds 2 contacts at Ampersand Biomedicines. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology around the same time
Companies in the same sectors as Ampersand Biomedicines that raised within 45 days of this round, from Fundz verified event records.
- Solena Materials raised $6.7M (Seed) on May 3, 2025.
- NewLimit raised $130M on May 2, 2025.
- Hoofprint Biome raised $15M (Series A) on May 2, 2025.
- Azora Therapeutics, Inc. (DE) raised $4.8M on May 2, 2025.
- AMPLY Discovery raised $1.8M (Seed) on May 1, 2025.
- Stately Bio raised $12M (Seed) on May 1, 2025.
Who to call at Ampersand Biomedicines, and when
A new round usually means Ampersand Biomedicines is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Ampersand Biomedicines raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Ampersand Biomedicines, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Ampersand Biomedicines. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Ampersand Biomedicines raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansAmpersand Biomedicines raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.